Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 3, 2001, Pages 825-831

  Dai, Diana ^a   Tang, Jun ^b   Rose, Randy ^b   Hodgson, Ernest ^b   Bienstock, Rachelle J ^a   Mohrenweiser, Harvey W ^c   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPYRIFOS; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; TESTOSTERONE;

ARTICLE; CATALYSIS; ENZYME ANALYSIS; ENZYME METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LIVER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TESTOSTERONE METABOLISM;

ALLELES; CHLORPYRIFOS; CHOLINESTERASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOME, HUMAN; HUMANS; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; TESTOSTERONE;

EID: 0035197548     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
2. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
3. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: Determination of Ki and dangers associated with high clearance drugs in general
4. Biotransformation of parathion in human liver: Participation of CYP3A4 and its inactivation during microsomal parathion oxidation
5. Organophosphrus compounds: An overview
6. Establishment of transgenic cell line CHL-3A4 and its metabolic activation
7. Genetic polymorphisms of CYP2C8 decrease the metabolism of the anticancer drug taxol and arachidonic acid
8. Lowry method of protein quantification: Evidence for photosensitivity
9. Cytochrome P450 3A: Ontogeny and drug disposition
10. Biotransformation enzyme polymorphism and pesticide susceptibility
11. Identification and functional characterization of eight CYP3A4 protein variants
12. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates
13. Association of CYP3A4 genotype with treatment-related leukemia
14. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4
15. Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene
16. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences
17. Cytochrome P-450 3A4: Regulation and role in drug metabolism
18. Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis
19. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam
20. Novel mutations of CYP3A4 in Chinese
21. Purification and properties of cytochrome P-450 from homogenates of human fetal livers
22. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
23. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
24. The CYP2 family: Models, mutants and interactions
25. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
26. PolyPhred: Automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing
27. A review of developmental aspects of cytochrome P450
28. More about: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
29. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
30. Automating the identification of DNA variations using quality-based fluorescence re-sequencing: Analysis of the human mitochondrial genome
31. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
32. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
33. Non-conservative amino acid substitutions exist at polymorphic frequency in DNA repair genes
34. Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxicity assays
35. Metabolism of chlorpyrifos by human cytochrome p450 isoforms and human, mouse, and rat liver microsomes
36. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
37. In vitro and in vivo drug interactions involving human CYP3A
38. CYP3A activity in African-American and European American men: Population differences and functional effect of the CYP3A4*1B5′- promoter region polymorphism
39. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis
40. Cloning and tissue distribution of a novel human cytochrome p450 of the cyp3a subfamily, cyp3a43
41. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity